Recruiter Hays announced a widely-predicted profits plunge for its full financial year as conditions in the labour market worsened.
At 97.5p per share, the Hays...
Getty ImagesThe first drug to slow the progression of early stage Alzheimer’s won’t be available on the NHS in England because health assessment body...
The UK’s health regulator has rejected a drug that can slow the progression of Alzheimer’s disease, saying its benefits were too small to justify...
Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of efficacy in slowing progression of...